Zheng Quan Shi Bao Wang·2025-08-27 00:17Company Overview - Tianxing Medical has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities and Jianyin International as joint sponsors [1] - Tianxing Medical is the largest domestic sports medicine company in China, providing treatment solutions for soft tissue injuries and sports rehabilitation covering joints such as shoulders, knees, and hips [1] - The company relies on self-developed implants, active devices, consumables, and surgical instruments, boasting the most comprehensive sports medicine product line in the Chinese market with 52 products, many of which are among the first approved domestically [1] Industry Insights - The Chinese sports medicine market is experiencing rapid growth, with a projected compound annual growth rate (CAGR) of 14.3% from 2024 to 2030, driven by an increase in the sports population, aging demographics, rising health awareness, and higher penetration rates of minimally invasive surgeries [1] - National policies encourage the development of domestic medical devices, and advancements in domestic brand technologies are expected to enhance the market penetration of local sports medicine providers [1] Financial Performance - By the end of 2024, Tianxing Medical's products are expected to be available in over 3,000 hospitals, including more than 1,000 tertiary hospitals [1] - The company anticipates achieving revenue of 327 million RMB and a profit of 95.39 million RMB for the fiscal year 2024 [1]